Clinical trial
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or…
NCT00295919 · Children's Hospital Los Angeles, Other · Completed
Key facts
| NCT number | NCT00295919 |
|---|---|
| Title | N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma |
| Official title | Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma |
| Lead sponsor | Children's Hospital Los Angeles, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug, Other |
| Interventions | fenretinide lipid matrix, ketoconazole, laboratory biomarker analysis, pharmacological study |
| Enrollment | 80 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2014 |
| Completion | May 1, 2015 |
| First posted | Feb 24, 2006 |
| Last update posted | Apr 7, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: